厄贝沙坦联合恩格列净治疗糖尿病肾病效果研究

Study on the Effect of Irbesartan Combined with Enpagliflozin in the Treatment of Diabetic Nephropathy

目的分析厄贝沙坦联合恩格列净治疗糖尿病肾病效果。方法于2016年10月—2020年3月研究将该院符合标准的78例糖尿病肾病患者纳为观察对象,数字法将其分成两组。对照组以厄贝沙坦治疗,观察组联合恩格列净治疗。比较两组疗效、血糖血压指标、肾功能指标等。结果观察组治疗总有效率为94.87%(37例),高于对照组,差异有统计学意义(P<0.05);观察组治疗后SBP为(112.32±2.18)mmHg,DBP为(73.23±4.28)mmHg,空腹血糖为(6.23±1.12)mmol/L,餐后2 h血糖为(7.92±1.21)mmol/L,均比对照组低,差异有统计学意义(P<0.05);观察组治疗后24-UP为(0.73±0.16)g/24 h,BUN为(7.54±0.23)mmol/L,GFR为(78.47±12.87)mL/(min·1.73 m2),差异有统计学意义(P<0.05)。结论厄贝沙坦+恩格列净用于糖尿病肾病的治疗对于调节血糖血压有积极作用,并能够缓解肾功能损害,对本病起到显著的治疗有效。

Objective To analyze the effect of irbesartan combined with empagliflozin in the treatment of diabetic nephropathy.Methods The study included 78 patients with diabetic nephropathy who met the criteria in the hospital as observation objects.The patients were enrolled in the group from October 2016 to March 2020.They were divided into two groups by number method.The control group was treated with irbesartan.The observation group was combined with enpagliflozin treatment,and the efficacy,blood glucose and blood pressure indexes,renal function indexes,etc.of the two groups were compared.Results The total effective rate was 94.87%(37 cases)in the observation group,which was higher than the control group,and the difference was statistically significant(P<0.05);the observation group after treatment SBP was(112.32±2.18)mmHg,DBP was(73.23±4.28)mmHg,fasting blood glucose was(6.23±1.12)mmol/L,and 2 h postprandial blood glucose was(7.92±1.21)mmol/L,which was lower than the control group,and the difference was statistically significant(P<0.05);24-UP after treatment in the observation group was(0.73±0.16)g/24 h,BUN was(7.54±0.23)mmol/L,GFR was(78.47±12.87)mL/(min·1.73 m2),and the difference was statistically significant(P<0.05).Conclusion Irbesartan+Enpagliflozin for the treatment of diabetic nephropathy has a positive effect on the regulation of blood glucose and blood pressure,and can alleviate the damage of renal function.It is effective in the treatment of this disease.